Analysis

Defence Therapeutics Inc Class A (DTC) Stock Analysis

Defence Therapeutics Inc Class A investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to DTC.

websiteDTC/analysis/DTC

Defence Therapeutics Inc Class A

Defence Therapeutics Inc Class A investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to DTC.

Stock profile

Ticker

DTC

Asset type

Stock

Market cap

$25.2M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

CAD

Ticker listings

Defence Therapeutics Inc Class A may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • DTC primary listing
  • DTCFF
  • A3CN14

Latest Defence Therapeutics Inc Class A news

Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors

Montreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology ...

Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors

Montreal, Quebec--(Newsfile Corp. - June 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology ...

Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian

Montreal, Quebec--(Newsfile Corp. - May 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology ...

Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities

Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing

Defence Therapeutics Announces Grant of Restricted Stock Units

Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnolo...

Research sections

Valuation

Review valuation context for Defence Therapeutics Inc Class A.

Future growth

Review future growth context for Defence Therapeutics Inc Class A.

Past performance

Review past performance context for Defence Therapeutics Inc Class A.

Financial health

Review financial health context for Defence Therapeutics Inc Class A.

Dividend

Review dividend context for Defence Therapeutics Inc Class A.

Management

Review management context for Defence Therapeutics Inc Class A.

Ownership

Review ownership context for Defence Therapeutics Inc Class A.

Other information

Review other information context for Defence Therapeutics Inc Class A.

Community

Review community context for Defence Therapeutics Inc Class A.